Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 26Unknown 5Terminated 3Not yet recruiting 3Withdrawn 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Peritoneal Diseases 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Pancreaticoduodenectomy × Clear all
NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases

NCT03718650 2021-02-08

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡